IN2012DN02702A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02702A
IN2012DN02702A IN2702DEN2012A IN2012DN02702A IN 2012DN02702 A IN2012DN02702 A IN 2012DN02702A IN 2702DEN2012 A IN2702DEN2012 A IN 2702DEN2012A IN 2012DN02702 A IN2012DN02702 A IN 2012DN02702A
Authority
IN
India
Prior art keywords
compounds
antagonists
lpa
medicaments
diseases
Prior art date
Application number
Other languages
English (en)
Inventor
Ryan Clark
Brian Andrew Stearns
Lucy Zhao
Thomas Jon Seiders
Deborah Volkots
Neannie M Arruda
David Nathan Zalatan
Original Assignee
Amira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43128100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN02702(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amira Pharmaceuticals Inc filed Critical Amira Pharmaceuticals Inc
Publication of IN2012DN02702A publication Critical patent/IN2012DN02702A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2702DEN2012 2009-10-01 2010-09-29 IN2012DN02702A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24787709P 2009-10-01 2009-10-01
PCT/US2010/050786 WO2011041461A2 (fr) 2009-10-01 2010-09-29 Composés polycycliques utiles en tant qu'antagonistes du récepteur de l'acide lysophosphatidique

Publications (1)

Publication Number Publication Date
IN2012DN02702A true IN2012DN02702A (fr) 2015-09-04

Family

ID=43128100

Family Applications (2)

Application Number Title Priority Date Filing Date
IN2702DEN2012 IN2012DN02702A (fr) 2009-10-01 2010-09-29
IN2730DEN2012 IN2012DN02730A (fr) 2009-10-01 2010-09-29

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN2730DEN2012 IN2012DN02730A (fr) 2009-10-01 2010-09-29

Country Status (20)

Country Link
US (3) US8664220B2 (fr)
EP (2) EP2483251B1 (fr)
JP (2) JP2013506680A (fr)
KR (1) KR20120097490A (fr)
CN (2) CN102656168B (fr)
AR (1) AR078495A1 (fr)
AU (1) AU2010300594A1 (fr)
BR (1) BR112012007102A2 (fr)
CA (1) CA2776779A1 (fr)
CL (1) CL2012000812A1 (fr)
EA (1) EA201270467A1 (fr)
GB (1) GB2474748B (fr)
IL (1) IL218962A0 (fr)
IN (2) IN2012DN02702A (fr)
MX (1) MX2012003723A (fr)
PE (1) PE20120997A1 (fr)
TN (1) TN2012000126A1 (fr)
TW (1) TWI415849B (fr)
UY (1) UY32923A (fr)
WO (2) WO2011041461A2 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
EP2462128B1 (fr) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Composés en tant qu'antagonistes du récepteur de l'acide lysophosphatidique
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
EP2582373A4 (fr) 2010-06-16 2013-10-30 Bruce Chandler May Utilisation de la lévocétirizine et du montélukast dans le traitement de la grippe, du rhume et d'une inflammation
CN103443098B (zh) 2011-01-30 2016-03-16 广州源生医药科技有限公司 作为溶血磷脂酸受体的拮抗剂的化合物、组合物及其应用
US8541587B2 (en) 2011-04-05 2013-09-24 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists
KR101369584B1 (ko) 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
AU2012258575B2 (en) * 2011-05-25 2017-03-02 Intermune, Inc. Pirfenidone and anti-fibrotic therapy in selected patients
CA2844469C (fr) * 2011-08-08 2019-08-20 Merck Patent Gmbh N-(benzimimdazol-2-yl)-cyclopropane-carboxamides en tant qu'antagonistes d'acide lysophosphatidique
MX2014001732A (es) 2011-08-15 2014-07-09 Intermune Inc Antagonistas del receptor de acido lisofosfatidico.
GB2493914A (en) * 2011-08-19 2013-02-27 Univ Jw Goethe Frankfurt Main Flurbiprofen and related compounds for the treatment of skin diseases
WO2013070879A1 (fr) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Méthodes de traitement de lésion de la moelle épinière par des antagonistes du récepteur du lpa
CN103987858A (zh) 2011-11-22 2014-08-13 英特芒尼公司 诊断和治疗特发性肺纤维化的方法
US20140329871A1 (en) * 2011-12-04 2014-11-06 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
CA2869541A1 (fr) * 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag Composes n-alkyltriazole utilises comme antagonistes de lpar
CA2879570A1 (fr) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associees a la resistance a des inhibiteurs de la tyrosine kinase de bruton (btk)
JP6176258B2 (ja) 2012-12-28 2017-08-09 宇部興産株式会社 ハロゲン置換へテロ環化合物
CN103965664B (zh) * 2013-01-25 2015-07-22 中国石油化工股份有限公司 一种碳黑粒子分散剂及其制备方法和应用
ES2770760T3 (es) * 2013-03-13 2020-07-03 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de lesiones traumáticas
EP3300734B1 (fr) 2013-03-13 2019-08-14 Inflammatory Response Research, Inc. Utilisation de lévocétirizine et de montélukast dans le traitement des maladies auto-immunes
CA2901413A1 (fr) 2013-03-13 2014-10-09 Bruce Chandler May Utilisation de levocetirizine et de montelukast dans le traitement de la vascularite
SG10201803833WA (en) 2013-03-15 2018-06-28 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
GB201314926D0 (en) * 2013-08-20 2013-10-02 Takeda Pharmaceutical Novel Compounds
EP3083601B1 (fr) * 2013-12-20 2020-09-09 Esteve Pharmaceuticals, S.A. Dérivés de pipéridine ayant une activité multimodale contre la douleur
JP2017078022A (ja) * 2014-02-28 2017-04-27 クミアイ化学工業株式会社 イソキサゾール誘導体及びそれを用いた農園芸用植物病害防除剤
JP6579103B2 (ja) 2014-06-27 2019-09-25 宇部興産株式会社 ハロゲン置換へテロ環化合物の塩
WO2016044095A1 (fr) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Lévocétirizine et montélukast dans le traitement de troubles médiés par une inflammation
CA2970043A1 (fr) * 2014-12-23 2016-06-30 Pharmacyclics Llc Combinaisons d'inhibiteurs de btk et regime de dosage
US9729562B2 (en) 2015-03-02 2017-08-08 Harris Corporation Cross-layer correlation in secure cognitive network
AU2016270373A1 (en) 2015-06-05 2018-01-04 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
CN107840842A (zh) * 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
WO2018106641A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles pour le traitement de maladies démyélinisantes
WO2018106646A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles pour traiter des maladies démyélinisantes
WO2018106643A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Azoles hétérocycliques pour le traitement de maladies de démyélinisation
WO2019041340A1 (fr) * 2017-09-04 2019-03-07 Eli Lilly And Company Composés inhibiteurs du récepteur 1 de l'acide lysophosphatidique (lpar1)
AU2018368332B2 (en) 2017-11-14 2022-05-12 Merck Sharp & Dohme Llc Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
EP3709986B1 (fr) 2017-11-14 2023-11-01 Merck Sharp & Dohme LLC Nouveaux composés biaryles substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
CN109776351B (zh) * 2017-11-15 2021-11-09 江苏优士化学有限公司 一种重氮乙酸酯连续化合成方法
US11447475B2 (en) 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
ES2944304T3 (es) 2017-12-19 2023-06-20 Bristol Myers Squibb Co Pirazol azinas de ácido ciclohexílico como antagonistas de LPA
WO2019126093A1 (fr) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Azines triazoles d'acide cyclohexyle utilisées en tant qu'antagonistes de lpa
US11352345B2 (en) 2017-12-19 2022-06-07 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as LPA antagonists
WO2019126086A1 (fr) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Azines isoxazole d'acide de cyclohexyle en tant qu'antagonistes de lpa
EA202091505A1 (ru) 2017-12-19 2020-09-22 Бристол-Маерс Сквибб Компани Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
EP3728196B1 (fr) 2017-12-19 2023-04-05 Bristol-Myers Squibb Company Acides carbamoyle cyclohexyliques à liaison o pyrazole utilisés en tant qu'antagonistes de lpa
CN112074515A (zh) * 2017-12-19 2020-12-11 百时美施贵宝公司 作为lpa拮抗剂的环己基酸异噁唑唑类
AU2018388482A1 (en) 2017-12-19 2020-07-30 Bristol-Myers Squibb Company Pyrazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
KR20200101957A (ko) 2017-12-19 2020-08-28 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산
CN112189010A (zh) 2017-12-19 2021-01-05 百时美施贵宝公司 作为lpa拮抗剂的三唑n-连接的氨基甲酰基环己基酸
CN108379275B (zh) * 2018-05-29 2020-05-22 中国医学科学院阜外医院 溶血磷脂酸、溶血磷脂酸受体3以及溶血磷脂酸受体3激动剂的应用
KR20210061383A (ko) 2018-09-18 2021-05-27 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로펜틸 산
KR20220024549A (ko) 2019-06-18 2022-03-03 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 이속사졸 카르복실산
EP3986553A1 (fr) 2019-06-18 2022-04-27 Bristol-Myers Squibb Company Acides cyclobutyl-carboxyliques utilisés comme antagonistes de lpa
EP4058144A1 (fr) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Pyridylsulfonamides de carbamate de triazole utilisées en tant qu'antagonistes du récepteur de lpa et leurs utilisations
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use
JP2023519892A (ja) 2020-03-27 2023-05-15 ランドス バイオファーマ インコーポレイテッド Ｐｌｘｄｃ２リガンド
EP4161936A1 (fr) 2020-06-03 2023-04-12 Gilead Sciences, Inc. Antagonistes du récepteur lpa et leurs utilisations
JP7490088B2 (ja) 2020-06-03 2024-05-24 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びその使用
WO2022240879A1 (fr) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Antagonistes du récepteur lpa et leurs utilisations
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物
CN114907282B (zh) * 2022-05-24 2023-08-22 华南理工大学 一种合成4-苯基烯基异噁唑衍生物的方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
ES2196396T3 (es) 1996-12-23 2003-12-16 Bristol Myers Squibb Pharma Co Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
JP3237608B2 (ja) 1997-04-21 2001-12-10 住友製薬株式会社 イソキサゾール誘導体
WO2000059902A2 (fr) 1999-04-02 2000-10-12 Du Pont Pharmaceuticals Company Sulfonyles aryles faisant office d'inhibiteurs du facteur xa
DK1258484T3 (da) 2000-02-18 2009-04-20 Kyowa Hakko Kirin Co Ltd Nye isoxazol- og thiazolforbindelser og anvendelse deraf som lægemidler
EP1277743A4 (fr) * 2000-03-28 2005-03-23 Nippon Soda Co Derived d'oxa(thia)zolidine et medicament anti-inflammatoire
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
WO2002040458A1 (fr) 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Derives d'isoxazole
WO2002062389A1 (fr) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
WO2003007991A1 (fr) 2001-07-17 2003-01-30 Ono Pharmaceutical Co., Ltd. Regulateurs de la secretion de suc pancreatique comprenant un agent de regulation du recepteur a lpa
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
AU2002367129A1 (en) 2001-12-25 2003-07-15 Ajinomoto Co., Inc. Organ fibrosis inhibitors
JP2003261545A (ja) 2001-12-28 2003-09-19 Takeda Chem Ind Ltd 神経栄養因子産生・分泌促進剤
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
US20050261298A1 (en) 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
WO2003062392A2 (fr) 2002-01-18 2003-07-31 Ceretek Llc Procedes pour traiter des pathologies associees a un recepteur d'edg
US20050101518A1 (en) 2002-01-18 2005-05-12 David Solow-Cordero Methods of treating conditions associated with an EDG-2 receptor
US7402605B2 (en) * 2002-03-05 2008-07-22 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
US20040014662A1 (en) 2002-05-08 2004-01-22 Per Lindquist Modulation of neural stem cells and neural progenitor cells
US7229987B2 (en) 2002-05-13 2007-06-12 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
WO2003099765A1 (fr) 2002-05-28 2003-12-04 Ono Pharmaceutical Co., Ltd. Derive de $g(b)-alanine et utilisation correspondante
WO2004002530A1 (fr) 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. Remede pour maladie chronique
AU2003241836A1 (en) 2002-10-03 2004-04-23 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
AU2003294315A1 (en) 2002-11-19 2004-06-15 Amgen Inc. Amplified genes involved in cancer
US20050065194A1 (en) 2003-01-16 2005-03-24 Geetha Shankar Methods of treating conditions associated with an Edg-2 receptor
US20040167132A1 (en) 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associted with an Edg-2 receptor
US20040192739A1 (en) 2003-01-16 2004-09-30 David Solow-Cordero Methods of treating conditions associated with an Edg-2 receptor
US7135469B2 (en) 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
CA2521189A1 (fr) 2003-04-11 2004-10-28 Gabor Tigyi Analogues d'acides lysophosphatidiques et inhibition de formation de neointima
WO2004099164A1 (fr) 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Diphenyl isoxazoles, pyrazoles et oxadiazoles substitues, destines au traitement d'une infection par le vhc
CN1791592B (zh) 2003-05-19 2012-07-04 Irm责任有限公司 免疫抑制剂化合物和组合物
WO2005012269A1 (fr) * 2003-08-05 2005-02-10 Ajinomoto Co., Inc. Nouveau compose azole
AU2004278042B2 (en) 2003-10-09 2012-02-09 University Of Tennessee Research Foundation LPA receptor agonists and antagonists and methods of use
JP4766384B2 (ja) 2003-12-19 2011-09-07 小野薬品工業株式会社 リゾホスファチジン酸受容体拮抗作用を有する化合物およびその用途
DE10360369A1 (de) 2003-12-22 2005-07-14 Bayer Cropscience Ag Amide
WO2005123671A1 (fr) * 2004-06-22 2005-12-29 Taisho Pharmaceutical Co., Ltd. Dérivé du pyrrole
JP2006096712A (ja) 2004-09-30 2006-04-13 Senju Pharmaceut Co Ltd Ｌｐａ受容体拮抗剤を含有する角膜知覚改善剤
US20080306124A1 (en) 2005-06-08 2008-12-11 Rainer Albert Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands
WO2007007588A1 (fr) 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. Compose comportant un groupe cyclique ayant un noyau plan
AU2006283175A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
CA2643670A1 (fr) 2006-02-27 2007-08-30 Sterix Limited Compose
US20090029949A1 (en) 2006-05-25 2009-01-29 Parrill-Baker Abby L GPCR Ligands Identified by Computational Modeling
WO2008014286A1 (fr) 2006-07-24 2008-01-31 University Of Virginia Patent Foundation Antagonistes du récepteur vinyle phosphonate acide lysophosphatidique
US20080051372A1 (en) 2006-08-24 2008-02-28 The Scripps Research Institute Methods utilizing cell-signaling lysophospholipids
WO2008024979A2 (fr) 2006-08-24 2008-02-28 The Scripps Research Institute Procédés d'utilisation de lysophospholipides de signalisation cellulaire
US20100143381A1 (en) 2007-03-12 2010-06-10 Andrew Tager Lysophosphatidic acid receptor targeting for lung disease
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
WO2009011850A2 (fr) 2007-07-16 2009-01-22 Abbott Laboratories Nouveaux composés thérapeutiques
MX2010011754A (es) 2008-05-05 2010-12-06 Sanofi Aventis Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino y su uso como productos farmaceuticos.
JP4933512B2 (ja) 2008-10-09 2012-05-16 住友化学株式会社 導光板
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
EP2462128B1 (fr) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Composés en tant qu'antagonistes du récepteur de l'acide lysophosphatidique
US20110082182A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
KR101579345B1 (ko) * 2010-01-06 2015-12-21 애플 인크. 검색 결과들 사이에서 방향을 맵핑하기 위한 장치, 방법 및 그래픽 사용자 인터페이스

Also Published As

Publication number Publication date
US10000456B2 (en) 2018-06-19
UY32923A (es) 2010-11-30
CN102656168B (zh) 2015-04-01
CN102770415A (zh) 2012-11-07
AR078495A1 (es) 2011-11-09
EP2483269A4 (fr) 2013-05-01
EP2483251A4 (fr) 2013-05-01
JP2013506680A (ja) 2013-02-28
MX2012003723A (es) 2012-05-08
GB201016312D0 (en) 2010-11-10
EA201270467A1 (ru) 2012-09-28
IL218962A0 (en) 2012-07-31
TWI415849B (zh) 2013-11-21
GB2474748A (en) 2011-04-27
TW201125862A (en) 2011-08-01
KR20120097490A (ko) 2012-09-04
EP2483269A2 (fr) 2012-08-08
WO2011041462A2 (fr) 2011-04-07
WO2011041461A2 (fr) 2011-04-07
CL2012000812A1 (es) 2012-09-07
US20140256744A1 (en) 2014-09-11
CN102656168A (zh) 2012-09-05
WO2011041462A3 (fr) 2011-08-11
CA2776779A1 (fr) 2011-04-07
US8664220B2 (en) 2014-03-04
WO2011041461A3 (fr) 2011-08-25
AU2010300594A1 (en) 2012-05-17
IN2012DN02730A (fr) 2015-09-11
JP2013506679A (ja) 2013-02-28
GB2474748B (en) 2011-10-12
CN102770415B (zh) 2014-09-24
US8778983B2 (en) 2014-07-15
EP2483251B1 (fr) 2016-10-26
BR112012007102A2 (pt) 2016-04-26
US20130072490A1 (en) 2013-03-21
EP2483251A2 (fr) 2012-08-08
US20110082164A1 (en) 2011-04-07
TN2012000126A1 (en) 2013-09-19
PE20120997A1 (es) 2012-08-01

Similar Documents

Publication Publication Date Title
IN2012DN02177A (fr)
IN2012DN02702A (fr)
IN2012DN00754A (fr)
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
PH12020550450A1 (en) Certain chemical entities, compositions and methods
WO2010077882A3 (fr) Antagonistes des récepteurs d'acide lysophosphatidique
PH12015501737B1 (en) Androgen receptor modulators and uses thereof
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
WO2010068775A3 (fr) Antagonistes d'alcyne de récepteurs d'acide lysophosphatidique
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2011156518A3 (fr) Modulateur du récepteur oestrogénique et utilisation de ces derniers
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
MY162604A (en) Heterocyclic compounds and uses thereof
IN2012DN02471A (fr)
TN2010000463A1 (en) Compositions and methods for preparing and using same